The Handoff: What a Competent Emergency Transfer Looks Like

A filler complication emergency transfer is a clinical procedure with a failure rate, not an administrative step at the end of one. Well-managed events go wrong at the handoff — not because the injector did the wrong thing in the chair, but because the information, the treatment and the patient arrived at the hospital separately, late, or not at all.

Michelle Langston's transfer protocol comes out of nearly thirty years in emergency and trauma nursing before she ever picked up a filler syringe, and it is built around four rules that sound simple and are routinely broken.

Never send the patient alone. Keep treating while you wait. Follow them and speak to the physician yourself. And do not let a patient leave your office in any circumstance until perfusion is stable.

Rule one: never tell the patient to go to the emergency room

Langston says it twice, which she rarely does. "Don't tell the patient just to go to the emergency room. Don't do that."

Five things go wrong when you do.

They may not go. A patient who is frightened, embarrassed about having had cosmetic treatment, worried about cost, or simply hoping it resolves is entirely capable of driving home instead. You will find out tomorrow.

They may go to the wrong hospital. Not every emergency department has interventional radiology or overnight ophthalmology cover. A patient choosing on their own will choose the nearest, or the one they know.

They arrive with no history. The patient does not know the product name, the lot, the volume, the plane, or the number of units of enzyme you have already given. They know "filler in my cheeks." That is the entire handoff, and it is not enough for anyone to act on.

They arrive as the wrong complaint. Presented by the patient, this is a cosmetic problem that hurts. Presented by a clinician, it is an iatrogenic arterial event with a clock on it. Those two presentations are triaged very differently, and the difference is measured in hours of ischemia.

They may deteriorate unaccompanied. In a car, alone, driving.

The alternative is not complicated: call 911, keep treating, and go with them.

Rule two: keep treating while you wait

Waiting time is treatment time. Langston: "Start your protocol. Start flooding, but call 911. You're going to continue that local protocol while waiting for those emergency services to come."

The reasoning is that the enzyme is in your hand and not in the ambulance. EMS provides transport and monitoring; they are not carrying hyaluronidase and they are not going to start flooding a facial territory en route. Every minute spent packaging a patient instead of treating them is a minute of ischemia you chose to accept.

So the sequence is parallel, not serial:

• The preparer calls 911 and gives the framing — suspected arterial occlusion following facial injection — then calls the medical director and any reciprocal practice.
• The injector continues flooding the affected territory and reassessing on the usual cycle.
• The recorder keeps the timeline running and assembles the transfer document.

The same logic applies to the marking and photography. Do not stop the series because an ambulance is coming; the last few frames before transport are the ones the receiving team will find most useful, because they establish direction.

Rule three: you follow them, and you speak to the physician

You do not ride in the ambulance. Langston's version is characteristically practical: "you can just hop right in the car, follow over. Let the ER doctor know."

Then you find the physician and you talk to them. Not the triage desk. Not a message left with a nurse. The attending.

Her framing of why is about standing rather than logistics: "That's going to show you're a real medical collaborator in your community."

That phrase carries more than it appears to. An aesthetic injector arriving in an emergency department with a cosmetic complication is not automatically extended clinical credibility. Some of that is unfair and some of it is earned by the field. Either way, it is the environment you are walking into, and the way you overcome it is by behaving like a referring clinician: identify yourself and your licence, hand over a written summary, speak in the structure they use, and say clearly what you are asking for.

Rule four: nobody leaves until perfusion is stable

This one governs the non-transfer case, and it is the rule most often broken by kindness.

"Do not make the patient leave until perfusion is stable. We need them to understand this."

A patient who is responding, whose colour is returning, who feels better and wants to go home at 7pm is a patient in the middle of a treatment, not at the end of one. Langston keeps patients for as long as it takes — "the patient might be there for a couple of hours" — and brings them back the next day, and daily thereafter until the situation has completely resolved.

If perfusion is not stable and you cannot make it stable, the patient is not going home. They are going to hospital.

When to transfer

Three triggers, and they do not all require a failed treatment cycle.

Any visual symptom — immediately and automatically. Blurred vision, a field defect, double vision, eye pain, ptosis, any of it. There is no observation tier for vision. Langston: "If there's a visual change, there is no watch and wait." For the anatomy of how injected material reaches the ophthalmic circulation, see our piece on whether injectables can cause blindness.

Poor response to the in-office protocol. The border is not retreating, capillary refill is not returning, or the picture is worsening across reassessment cycles.

A non-HA agent. If the occlusive material is calcium hydroxylapatite or poly-L-lactic acid, the enzyme is not degrading it and your in-office cycle is a holding action rather than definitive treatment. The trigger moves to the point of suspicion. This is covered in full in the companion piece on what hyaluronidase cannot do.

Choosing the destination

Not the nearest emergency department. The right one.

Langston specifies the capability she wants: "we want to get them to where we can do an IR-guided dissolution," and elsewhere, "preferably to an area that has interventional radiology so that we can get this filler targeted quickly."

Evidence honesty is required here. Image-guided intra-arterial delivery of hyaluronidase for filler embolism is described in case reports and small series, and it is an escalation target rather than an established standard of care with trial support. Langston teaches it as the capability to seek, and she is a highly experienced emergency clinician, but a reader should understand the evidence base for what it is. What is not in doubt is the general principle: a facility with more diagnostic and interventional capability than your treatment room is where an unresolving arterial event belongs.

For ocular symptoms, you also want ophthalmology cover, and overnight cover specifically — many departments have it during the day and not at 9pm.

Find this out this week, not during an event. Make a list of the hospitals within reasonable transport distance and, for each one, note whether they have interventional radiology, whether it is available out of hours, and whether ophthalmology is on call overnight. Put the list on the same sheet as your emergency phone numbers. This is a phone call to each hospital's switchboard and it takes an afternoon.

What the emergency physician actually needs to hear

Use SBAR. It is the structure hospital clinicians hand over in, it takes about sixty seconds, and using it marks you immediately as someone to listen to.

Situation

Who you are, your licence and credential, your callback number, and one sentence on what is happening.

"I'm Michelle Langston, I'm a family nurse practitioner, I treated this patient with dermal filler ninety minutes ago and she has a suspected arterial occlusion in the left nasolabial territory. My mobile is —."

Say the words arterial occlusion or arterial embolisation of dermal filler. Do not say "a reaction," "a complication," or "swelling." Those words route the patient towards allergy, cellulitis and observation. You are describing ischemia with a time course, and the language has to carry that.

Background

The treatment itself, in specifics:

• Product — brand name, and the class in plain terms. Hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid. Lot number if you have it. If the product is not hyaluronic acid, say so explicitly and say that hyaluronidase does not degrade it.
• Volume injected, and aliquot size per pass.
• Anatomic site, in anatomical language, and the plane and depth.
• Needle or cannula, and gauge.
• Time of injection.
• Time and nature of symptom onset, and who noticed it first.

Assessment

What you have found and what you have done. This is the part that distinguishes a competent transfer from an alarming one.

• Everything you have given: hyaluronidase, which product — recombinant human or animal-derived — total units, number of doses, the time of each, and the response to each. "Three doses, total 1,350 units, at 15-minute intervals, partial return of capillary refill after the second, no further improvement since."
• Current findings: capillary refill, colour, skin temperature, pain, any visual symptom, and the trend across your marked borders.
• Adjuncts given, if any.
• Allergies, current medications including anticoagulants, and relevant history.

Recommendation

Say what you are asking for. Referring clinicians who do not make an ask get triaged as information.

"I'm asking for interventional radiology assessment, ophthalmology review given the visual symptom, and further hyaluronidase — I've brought my own supply and my full record."

Hospitals already stock the enzyme — but do not rely on it

This is one of Langston's more useful observations, and it needs handling with care.

"This may not be a physician that understands that hospitals do have hyaluronidase in their pharmacy. We use it in the operating room. We use it in interventional radiology all the time."

She is right that hyaluronidase is a hospital pharmacy item in many institutions, used as a spreading agent and in the management of certain extravasation injuries, and that an emergency physician who has not encountered a filler embolism before may not know it is available to them. That is a genuinely valuable thing to be able to say.

Say it as a prompt, not as a claim: your pharmacy may well carry hyaluronidase — it's used as a spreading agent in theatre and in IR — and it's worth having them check. Offer it; do not assert it. Stocking varies by institution and you cannot verify another hospital's formulary from your treatment room.

And regardless: bring your own. Langston's whole approach assumes you keep treating, which means the supply travels with you. Do not hand your patient over into a gap while a pharmacy is located.

The transfer bag

Assemble it once, keep it ready, and grab it on the way out.

• Your hyaluronidase supply, in date, with diluent and syringes.
• The paper record from the event — times, units, vials, findings.
• Printed or accessible copies of the photographic series, including the marked borders with their timestamps.
• A one-page written summary in SBAR order, ideally on a pre-printed form with blanks.
• The product's packaging or lot information.
• The patient's chart summary: allergies, medications, relevant history.
• The signed consents, including the hyaluronidase consent.
• Your licence and contact details.

The one-page written summary matters more than anything else on the list. Verbal handovers are repeated, misremembered and lost at every change of team. A written sheet stays with the chart and reaches the physician who takes over at shift change.

Pre-build the transfer before you need it

Everything above should exist on paper before an event, because none of it can be created during one.

The transfer sheet. A single side, SBAR headings, blanks for product, lot, volume, site, plane, times, doses and findings. Print twenty. Someone fills one in while you inject.

The hospital capability list. Which facility has interventional radiology, out of hours, and ophthalmology cover overnight. With switchboard numbers.

The EMS script. One sentence, written down, so that whoever makes the call does not have to compose it: "Suspected arterial occlusion following facial injection, patient is conscious and stable, we are treating on site and need transport to —."

The introduction. Consider introducing yourself to your likely receiving emergency department before you ever need them. A short letter or a conversation explaining what your practice does, what complications you manage, what you would call about, and what you would bring. It costs an hour and it changes the reception you get.

After the handoff, you do not disappear

Transfer is not discharge of responsibility.

Stay reachable. Provide the records the hospital asks for. Follow up with the patient the same day and the next.

When the patient comes back to you, care resumes on the same terms as any complication: daily review until complete resolution, serial photography, and no reinjection of that territory for at least two to three weeks, until full tissue recovery is established. Late compromise still needs catching — blistering or pustules at day three indicate continuing ischemia and prompt a retreatment decision rather than reassurance. Langston also includes hyperbaric oxygen therapy as a pathway to have identified in advance: "you might want to have that all part of your emergency protocol — where would you send the patient, what would you do."

And debrief your team, the same day, without blame.

These protocols, intervals and figures reflect Michelle Langston's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.

The anatomical knowledge that lets you describe the affected territory precisely to a physician who is not an injector is taught in Empire's Anatomical Based Aesthetics Training and, for the highest-risk regions, Master Eye & Nose Injection Training; complication preparedness runs alongside technique in Complete Dermal Filler Training. For the treatment you are continuing throughout the transfer, see our overview of filler dissolving, and for distinguishing expected responses from ischemia, common lip filler reactions.

Related guides in this cluster

Part of Vascular Occlusion: Recognition and Response.

Clinical GuideThe Expected Filler Injection Response — Building the Baseline That Lets You Recognize IschemiaThe expected filler injection response — erythema, edema, ecchymosis — and how a trained normal baseline makes early ischemia recogniza Clinical GuideThe Golden Triangle — Why the Filler Deposit Site Isn't Where You Put the Needle InThe filler deposit site sits at the needle tip, not the entry point — about half an inch away, further with a cannula. Why that gap dec Clinical GuideImmediate, Early and Late — The Three Windows of Vascular Occlusion OnsetVascular occlusion onset is not one moment. Organize the picture into immediate, early and late windows — detection runs days past the